disclaim financi forecast recommend current review
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim dec
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
continu post mix result follow weak
stem omega integr issu return brand
competitor like johnson johnson store shelv
competit pressur compani prescript topic
busi previous consid store-brand
market share gain competitor manufactur issu
consum seek lower-cost option recess
unsustain think oper sustain
reason growth execut turnov remain concern
think resili consum health busi retain
august manag announc plan separ
prescript topic busi make perrigo nearli
pure play private-label brand over-the-count drug
long term think consum health busi support
steadi growth littl risk reimburs concern
new entrant increas peer like teva
becom focus space on-going market penetr
private-label product intern portfolio expans
over-the-counter approv exist prescript drug help bolster
growth divest prescript busi remov
exposur volatil retail pharmaci market
omega deal under-perform tarnish manag
merger acquisit streak still think
compani capital-alloc decis enhanc long-term
major player european over-the-counter market provid
necessari brand portfolio salesforc compet among
fragment custom base retail region
acquisit food drug
unlik over-the-counter drug store-brand penetr product
categori remain rel small like seek
leverag store-brand retail expertis expand new
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
largest store-brand over-the-count pharmaceut
consum healthcar brand consum healthcar prescript
pharmaceut plan divest prescript
segment unit state sell product
stock-keep unit follow acquisit omega pharma
approxim compani revenu come outsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
place review transfer
coverag new analyst expect publish new fair
valu estim second quarter
lower fair valu estim per share
follow notic amend assess noa
receiv irish offic revenu commission
tax liabil eur billion relat past tysabri
transact potenti regulatori delay
compani gener version teva proair addit
potenti sale price compani prescript
topic busi remain potenti near-term
catalyst could shift fair valu manag
previous anticip late approv gener
proair may fall middl later
multipl approxim
growth fuel low-single-digit growth
consum health nutrit segment combin
return low-single-digit growth prescript drug
segment follow declin revenu
competit price pressur think
product volum face pressur competit
over-the-counter market modestli intensifi market share gain
store-brand product slow econom condit
reduct sale certain under-perform non-core
asset help stabil profit
dont anticip major futur margin expans
compani consum health nutrit prescript
drug segment probabl continu reli
omega salesforc distribut infrastructur
expand oper throughout europ tax manufactur
administr area offer long-term potenti cost
companywid oper margin eventu rise
back mid teen next year compani
make improv integr omega
estim long-term corpor tax rate
remain near assum cost capit
approxim compani
despit rel stabil private-label
consum health busi assign firm high
uncertainti rate due recent volatil gener
prescript topic segment on-going issu
integr omega sale tysabri royalti
remov uncertainti compani futur cash
bull case assum continu share gain
gener over-the-counter market larger new product launch lead
five-year averag organ growth
consum brand consum health segment also
recov midsingl digit thank new
launch proair stock price per share
scenario reach oper margin
thank limit price pressur on-going effici
gain success integr omega better-than-expect
contrast bear-cas scenario assum slow custom
accept store-brand
weak prescript topic busi
greater-than-expect competit price pressur
over-the-counter market model low-single-digit growth
across consum health segment on-going
competit pressur prescript segment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
omega asset diminish confid
creat econom profit long term
abil challeng gradual improv growth
profit seen much recent past
probabl difficult sustain
acquisit tysabri royalti histor
made larg portion bottom line
manag sold asset earli
think neg econom moat trend
think rel larg exposur over-the-counter gener
drug market threaten erod firm cost advantag
time addit new competit prescript
topic market like continu diminish firm
histori stabl price segment
near scenario yield fair valu estim
think possess econom moat
consid gener drug industri whole
entri remain low product remain highli commodit
industri remain fairli fragment despit past
consolid economi scale shelf space
manag uniqu packag capabl help
entrench firm custom suppli chain
consum health oper also fifth-largest
brand consum health compani europ follow
omega acquisit brand reput help
support price power market share addit
manufactur regulatori barrier prescript
topic segment recent support above-averag
growth profit regardless think continu
rise new entrant particularli low-cost emerg
market continu diminish cost advantag larger
peer like given recent price eros
prescript topic unit combin poor perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
odifficult econom condit push price-
ojohnson johnson return over-the-counter market
gradual improv economi slow
market share gain store-brand segment
market leader gener releas
prescript drug receiv over-the-counter approv
particip major domest launch
manufactur product packag shelf-spac
manag high volum stock-keep
unit -- tend limit private-label competit
omanag aggress acquisit strategi
depress return capit acquisit live
expect overpay asset remain
credibl threat sharehold
recent deal help diversifi
oper major retail
repres larg concentr
revenu give compani littl price power
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
like mani peer specialti pharma industri
appetit acquisit increas financi
leverag year believ cash flow
enabl compani meet financi oblig
includ small dividend gradual reduc debt
burden billion acquisit omega
billion acquisit follow number smaller deal
like sergeant paddock lab
past year push total debt close billion
end recent manag reduc
financi leverag compani sold tysabri
royalti stream billion cash million
net debt/ebitda time
estim fall near base current
perform announc acquisit
despit rel stabil private-label
consum health busi assign firm high
uncertainti rate recent volatil gener
prescript topic segment on-going issu
integr omega sale tysabri royalti
remov uncertainti compani futur cash
flow perrigo possess consolid custom base
among larg consolid retail chain wholesal
acquisit omega pharma boost
diversif alon account almost
revenu follow combin omega although
undoubtedli firmli embed custom
suppli chain unlik shift anoth supplier would
disastr consequ low-cost
emerging-market competitor abl
success compet higher-valu
store-brand over-the-counter market dont predict drastic shift
market share medium term earli
manag sold tysabri royalti stream
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres signific portion compani cash
flow face new competit product like roch
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
give standard stewardship rate
papa leav run valeant follow
exit cfo judi brown ceo john hendrickson
announc retir middl uwe
rohrhoff began role ceo earli rohrhoff
abruptli depart late murray kessler take
rein kessler former ceo lorillard also
previou consum packag good experi
altria vlasic food campbel soup ron
winowiecki also switch interim perman cfo
earli winowiecki variou
papa tenur ceo chairman manag
made mix capital-alloc decis opinion
mani deal help improv competit advantag
perman erod return capit led
impair paddock lab pbm hold
acquisit help moat give compani
stronghold high-barrier-to-entri infant nutrit
topic drug market view deal
lower compani tax rate omega expand
oper europ gone accord plan
expect return capit return compani
histor norm anytim soon under-perform
lead impair end suggest
manag bit could chew recent
view mostli shareholder-friendli firm
appreci portion
compens stem partial return capit
separ ceo chairman board role
rolf classon whose execut
includ bayer becam
chairman board earli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
suffer self-inflict wound
concern remain horizon feb
despit fourth-quart revenu declin
slightli ahead expect report weaker
bottom-lin perform expect thank mostli
unexpect downtim infant manufactur facil
quarter lop year-end earn
per share manag expect temporari issu
resolv end quarter still face
concern poor servic level consum
health busi price pressur prescript topic
segment overhang potenti tysabri-rel tax
penalti ireland uncertainti strateg
direct busi new ceo murray kessler hope
transit self-car compani plan
updat investor self-car strateg plan
investor day may also includ plan
separ prescript topic busi
skeptic growth opportun expand
product scope busi especi either
brand innov area doesnt
establish record less regul lower-barrier-to-
entri product categori may lower fair valu
estim slightli firm near-term issu
plan keep long-term project place
also keep no-moat rate unchang
mileston payment first quarter
follow notic amend assess receiv
irish offic revenu commission tax
liabil eur billion lower fair valu
estim per share ad
futur tax plu estim interest potenti fee
model appeal noa issuanc
delay time payment theoret
revers potenti liabil leav no-moat
rate unchang
estim could afford pay futur liabil
push year recent report
cash balanc million sepemb
estim nearli million oper cash flow annual
next five year howev larg potenti liabil
would like limit share repurchas debt pay
possibl futur acquisit
noa stem handl purchas
full right tysabri includ billion
up-front cash plu royalti inherit royalti
stream late part billion cash stock
merger part tax invers strategi perrigo
sold right royalti stream royalti pharma
billion cash million
mileston payment noa contend
recognit payment trade incom
benefit lower tax rate incorrect
chargeabl gain higher effect tax rate
report surprisingli weak anim health
prescript topic
plan lower fair valu estim
compani post weak anim health franchis
prescript topic segment third quarter
manag lower year-end outlook nearli
billion revenu adjust ep
meaning estim surpris
magnitud pressur face quarter
no-moat neg trend rate reflect belief
intensifi competit weve seen gener
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
market might well establish
addit mix record new area
perspect compani entri infant
nutrit mostli posit struggl
anim health exampl
industri last coupl year like
except anim health prescript topic
oper busi continu post
million impair revenu reduct anim
health sale loss partner product remaind
consum health busi howev report posit
growth rel stabl margin estim
meanwhil intern divis post encourag
organ growth exclud divestitur currenc
effect well adjust oper margin
show evid manag on-going
declin sale profit thank increas
competit exist product combin lack
new product launch sale fell adjust
oper margin declin basi point
expect even though model
alreadi incorpor margin eros segment
compani continu compel limited-
competit product like proair pipelin howev
topic busi slightli
insul nich portion market quarter result
suggest mani complex categori face similar
competit headwind broader gener industri
new ceo murray kessler seem like focu
tangenti self-car categori broader private-label
market also seem emphas organ growth
opportun rather need acquisit tend
agre primarili private-label drug busi
limit opportun growth widen scope
busi could favor hand
concern compet lower-barrier-to-entri
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
